Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2013 by University of California, Irvine
Information provided by (Responsible Party):
Chao Family Comprehensive Cancer Center, University of California, Irvine Identifier:
First received: March 21, 2011
Last updated: June 19, 2013
Last verified: June 2013
No Study Results Posted on for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: December 2017
  Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)